The novel encorafenib and binimetinib combination, already approved for BRAF-mutated melanoma, has been investigated in two different phase II trials (ENCO-BRAF, OCEANII) for NSCLC patients. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.